Results 71 to 80 of about 25,204 (165)

Unveiling the Prognostic Power of Circulating Tumor DNA in Multiple Myeloma: A Systematic Review and Updated Meta-Analysis. [PDF]

Cancer Med
Ying W, Fan L, Li R, Qu X.
europepmc   +1 more source

MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL. [PDF]

Blood Adv
Altıntaş I, Morehouse C, Favaro E, Rana A, Karavitis J, Szafer-Glusman E, Zhao K, Linton K, Danilov A, LaCasce AS, Falchi L, Okosun J, Ahmadi T, Fereshteh M, Jure-Kunkel M, Soong D, Steele AJ.   +16 more
europepmc   +1 more source

Efficacy of circulating tumour DNA in guiding postoperative adjuvant chemotherapy for resectable colorectal cancer: A meta-analysis based on cohort studies. [PDF]

Oncol Lett
Ruan J, Shi W, Shi W, Zhang X, Chen Y, Feng X, Song J.   +6 more
europepmc   +1 more source

Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions. [PDF]

Front Oncol
Zheng J, Chi L, Guo Y.
europepmc   +1 more source

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma. [PDF]

Cancers (Basel)
Steimle AK, Forati AM, Zhou AY, McCracken T, Hosny MM, Rahimi G, Patel JD, Burkey C, Caraway J, Huppe T, Wood A, Harris MS, Birbrair A, Ayuso JM, Sahasrabudhe DM, Hollnagel F, Doolittle GC, Burr AR, Mathew NS, In GK, Victor A, Ma VT.   +21 more
europepmc   +1 more source

Breaking the ctDNA sensitivity barrier

, 2017
O estudo da biologia molecular do cancro tem permitido avanços científicos com impacto na prática clínica, mudando o paradigma de abordagem terapêutica convencional, sistémica, para uma abordagem personalizada. No entanto, a caracterização molecular de tumores sólidos só é possível através da biopsia do tecido, uma estratégia altamente invasiva com ...
openaire   +1 more source

Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma. [PDF]

J Transl Med
Heidrich I, Streckenbach A, Rautmann C, Freiberg H, Kött J, Geidel G, Rünger A, Zell T, Roeper C, Hansen-Abeck I, Abeck F, Schneider SW, Smit DJ, Pantel K, Gebhardt C.   +14 more
europepmc   +1 more source

ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions. [PDF]

Onco Targets Ther
Al-Shamsi HO, Rafii S, Tirmazy SHH, Mukherji D, Abuhelwa AY, Iqbal F, Abdelwahab SI, Kourie HR, Abdelrahim M.   +8 more
europepmc   +1 more source

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial. [PDF]

Nat Cancer
Marsoni S, Montagut C, Pietrantonio F, Sartore-Bianchi A, Lazzari L, Bergamo F, Zampino MG, Tarazona N, Mandalà M, Tamberi S, Elez E, Santos Vivas C, Luraghi P, Prisciandaro M, Tosi F, Ciardiello D, Vidal J, Seguì V, Palazzo M, Maddalena G, Bencardino K, Taglialatela I, Guix M, Rulli E, Vettore V, Morano F, Isella C, Crisafulli G, Patelli G, Medico E, Bardelli A, Cervantes A, Torri V, Tabernero J, Siena S, Lonardi S.   +35 more
europepmc   +1 more source

Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.

JAMA Oncol
Cunningham N, Cutts RJ, Swift C, Coakley M, Sritharan P, Dunne K, Dewan M, Kilburn L, Goddard K, Hall P, Harper-Wynne C, Macpherson IR, Okines A, Wardley A, Waters S, Palmieri C, Winter M, Bliss J, Garcia-Murillas I, Turner NC.   +19 more
europepmc   +1 more source